Lead, Blood (Capillary)
Ordering Recommendation
Detect exposure to lead primarily in pediatric patients.
Quantitative Inductively Coupled Plasma-Mass Spectrometry
1-2 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Trace Elements Test Request Form Required (ARUP form #32990)Trace Elements Test Request Form Required (ARUP form #32990)

Specimen Collection and HandlingSpecimen Collection and Handling

Specimen Required
Patient Preparation
Clean puncture site well with soap and water before collection procedure begins.  
Lavender Microtainer(EDTA).  
Specimen Preparation
Invert specimen 10 times to prevent clot formation. Transport 0.5 mL whole blood. (Min: 0.3 mL)  
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated.  
Unacceptable Conditions
Heparin anticoagulant. Frozen specimens.  
Trace Elements requisition form may be required (ARUP form #32990).  
If the specimen is drawn and stored in the appropriate container, the lead values do not change with time  
Reference Interval
0.0-4.9 µg/dL  
Interpretive Data
Elevated results may be due to skin or collection-related contamination, including use of a noncertified lead-free tube. Elevated levels of blood lead should be confirmed with a second specimen collected in a lead-free tube.

Repeat testing is recommended prior to initiating chelation therapy or conducting environmental investigations of potential lead sources.

Information sources for reference intervals and interpretive comments include the "CDC Response to the 2012 Advisory Committee on Childhood Lead Poisoning Prevention Report" and the "Recommendations for Medical Management of Adult Lead Exposure, Environmental Health Perspectives, 2007." Thresholds and time intervals for retesting, medical evaluation, and response vary by state and regulatory body. Contact your State Department of Health and/or applicable regulatory agency for specific guidance on medical management recommendations.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Age Concentration Comment
All ages 5-​9.9 µg/dL Adverse health effects are possible, particularly in children under 6 years of age and pregnant women. Discuss health risks associated with continued lead exposure. For children and women who are or may become pregnant, reduce lead exposure.
All ages 10-​19.9 µg/dL Reduced lead exposure and increased biological monitoring are recommended.
All ages 20-​69.9 µg/dL Removal from lead exposure and prompt medical evaluation are recommended. Consider chelation therapy when concentrations exceed 50 µg/dL and symptoms of lead toxicity are present.
Less than 19 years of age Greater than 44.9 µg/dL Critical.  Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.
Greater than 19 years of age Greater than 69.9 µg/dL Critical.  Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0020745Lead, Blood (Capillary)10368-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • BLL
  • Capillary blood level
  • Lead (Pediatric)
  • Pb
  • Pb, Blood
  • Pb, Pediatric
  • Pb, Whole Blood